Novo Nordisk joins the legal battle for drug shortage to lose weight

Novo Nordisk A/S. It can intervene in a demand between the FDA and the drug compounds on whether their drugs of great success, Wegovy and Ozempic are still scarcity, a federal judge ordered on Wednesday.

Judge Mark T. Pittman of the United States District Court for the Northern District of Texas governed That good cause exists for the intervention of Novo in a case Brought by the Association of Outsourcing Facilities that challenges the decision of February 21 of food and medicines that ended the scarcity of Semaglutida de Novo, the active ingredient used in the company’s loss and diabetes drugs.

Pittman on Tuesday first denied The motion of the manufacturer to intervene after ruling was premature, but reversed the course on Wednesday after Novo presented a renewed motion.

The Outsourcing Facilities Association challenges if the FDA legally certain That the shortage was resolved, which meant that drug compounds (pharmacists, facilities and others that mix ingredients to create medications in scarcity) stop producing copies of drugs.

Novo looked for intervene In the case, stating that he had a clear and substantial interest in what the FDA and drug compounds were struggling and because it is the only company that makes the psemaglutida approved by the FDA.

Drug compounds in a separate demand are also challenging the decision of the FDA that determined Eli Lilly & Co.Tirzepatida shortage is resolved.

The case is Outsourcing facilities association v. Food and medication managementND Tex., No. 4: 25-CV-00174, Order presented 3/5/25.